Skip to content

Clinical study and mechanism explanation of Sanhuang Zengmian Tang's regulation of fibroblast aging and treatment of qi and yin deficiency type melasma based on SCF/c-kit/MAPK signaling pathway

Clinical study and mechanism explanation of Sanhuang Zengmian Tang's regulation of fibroblast aging and treatment of qi and yin deficiency type melasma based on SCF/c-kit/MAPK signaling pathway

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001907
Enrollment
Unknown
Registered
2025-10-15
Start date
2025-08-31
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chloasma

Interventions

control group:Oral Vitamin C+E
Observers:Oral administration of vitamin C+E and Sanhuang Zengmian Tang with modifications

Sponsors

Affiliated Hospital of Chengdu University of Traditional Chinese Medicine (Sichuan Provincial Hospital of Traditional Chinese Medicine)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 55 Years

Inclusion criteria

Inclusion criteria: (1) Meets the diagnostic criteria of traditional Chinese and Western medicine; (2) The age range is between 25 and 55 years old, and no relevant treatment was received within one month before the visit; (3) Complete and reliable clinical case data; (4) Those who voluntarily sign an informed consent form, are able to cooperate with treatment, and can be followed up.

Exclusion criteria

Exclusion criteria: (1) In the period of preparing for pregnancy, pregnancy, or lactation; (2) Patients with severe primary diseases of various organ systems, endocrine system diseases, malignant tumors, mental illnesses, hematopoietic system diseases or thrombophilia tendencies, and previous allergies; (3) Individuals who have received local cosmetic treatment at the test site within 6 months prior to the start of the study; (4) Those who cannot avoid direct sunlight exposure; (5) Those who cannot take medication and follow up according to regulations, cannot judge the efficacy, or have incomplete data that affects the assessment of efficacy.

Design outcomes

Primary

MeasureTime frame
Enzyme linked immunosorbent assay (ELISA) was used to measure the levels of SOD and MDA in the serum of patients;

Secondary

MeasureTime frame
OLINK targeted proteomics technology is used to detect the protein expression of SCF, c-kit, MAPK, MITF, and TYR, factors related to the SCF/c-kit/MAPK pathway.;General Treatment Completion Evaluation Scale;Melasma Severity Index (MASI) score;Skin imaging evaluation;Traditional Chinese Medicine Syndrome Score;

Countries

China

Contacts

Public Contactwujingping

Affiliated Hospital of Chengdu University of Traditional Chinese Medicine

wujingping2006@126.com15928747715

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026